Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.

Knerr PJ, Mowery SA, Finan B, Perez-Tilve D, Tschöp MH, DiMarchi RD.

Peptides. 2019 Nov 28:170225. doi: 10.1016/j.peptides.2019.170225. [Epub ahead of print] Review.

PMID:
31786282
2.

Glucagon-like peptide 1 (GLP-1).

Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH.

Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. Review.

3.

Corrigendum to "Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice" [Molecular Metabolism 23 (2019) 75-81].

Jall S, Finan B, Collden G, Fischer K, Dong X, Tschöp MH, Müller TD, Clemmensen C.

Mol Metab. 2019 Dec;30:264. doi: 10.1016/j.molmet.2019.11.002. No abstract available.

4.

Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression.

Nason SR, Kim T, Antipenko JP, Finan B, DiMarchi R, Hunter CS, Habegger KM.

Endocrinology. 2020 Jan 1;161(1). pii: bqz013. doi: 10.1210/endocr/bqz013.

PMID:
31673703
5.

Insulin-like peptide 5 fails to improve metabolism or body weight in obese mice.

Zaykov AN, Gelfanov VM, Perez-Tilve D, Finan B, DiMarchi RD.

Peptides. 2019 Oct;120:170116. doi: 10.1016/j.peptides.2019.170116. Epub 2019 Jul 23.

PMID:
31348991
6.

A Disulfide Scan of Insulin by [3 + 1] Methodology Exhibits Site-Specific Influence on Bioactivity.

Brunel FM, Mayer JP, Gelfanov VM, Zaykov AN, Finan B, Perez-Tilve D, DiMarchi RD.

ACS Chem Biol. 2019 Aug 16;14(8):1829-1835. doi: 10.1021/acschembio.9b00420. Epub 2019 Aug 6.

PMID:
31343157
7.

Glucagon lowers glycemia when β-cells are active.

Capozzi ME, Wait JB, Koech J, Gordon AN, Coch RW, Svendsen B, Finan B, D'Alessio DA, Campbell JE.

JCI Insight. 2019 Jul 23;5. pii: 129954. doi: 10.1172/jci.insight.129954.

8.

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes.

Finan B, Capozzi ME, Campbell JE.

Diabetes. 2019 Jun 9. pii: dbi190004. doi: 10.2337/dbi19-0004. [Epub ahead of print]

PMID:
31178432
9.

Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety.

He R, Finan B, Mayer JP, DiMarchi RD.

Molecules. 2019 May 14;24(10). pii: E1855. doi: 10.3390/molecules24101855. Review.

10.

GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice.

Décarie-Spain L, Fisette A, Zhu Z, Yang B, DiMarchi RD, Tschöp MH, Finan B, Fulton S, Clemmensen C.

Neuropharmacology. 2019 Jun;151:55-63. doi: 10.1016/j.neuropharm.2019.03.035. Epub 2019 Apr 1.

PMID:
30946847
11.

Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.

Ratner C, He Z, Grunddal KV, Skov LJ, Hartmann B, Zhang F, Feuchtinger A, Bjerregaard A, Christoffersen C, Tschöp MH, Finan B, DiMarchi RD, Leinninger GM, Williams KW, Clemmensen C, Holst B.

Diabetes. 2019 Jun;68(6):1329-1340. doi: 10.2337/db18-1009. Epub 2019 Apr 1.

12.

Pirt deficiency has subtle female-specific effects on energy and glucose metabolism in mice.

Jall S, Finan B, Collden G, Fischer K, Dong X, Tschöp MH, Müller TD, Clemmensen C.

Mol Metab. 2019 May;23:75-81. doi: 10.1016/j.molmet.2019.02.011. Epub 2019 Mar 7. Erratum in: Mol Metab. 2019 Dec;30:264.

13.

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.

Mroz PA, Finan B, Gelfanov V, Yang B, Tschöp MH, DiMarchi RD, Perez-Tilve D.

Mol Metab. 2019 Feb;20:51-62. doi: 10.1016/j.molmet.2018.12.001. Epub 2018 Dec 5.

14.

Publisher Correction: Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes.

Clemmensen C, Jall S, Kleinert M, Quarta C, Gruber T, Reber J, Sachs S, Fischer K, Feuchtinger A, Karlas A, Simonds SE, Grandl G, Loher D, Sanchez-Quant E, Keipert S, Jastroch M, Hofmann SM, Nascimento EBM, Schrauwen P, Ntziachristos V, Cowley MA, Finan B, Müller TD, Tschöp MH.

Nat Commun. 2018 Nov 20;9(1):4975. doi: 10.1038/s41467-018-07479-1.

15.

Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.

Clemmensen C, Finan B, Müller TD, DiMarchi RD, Tschöp MH, Hofmann SM.

Nat Rev Endocrinol. 2019 Feb;15(2):90-104. doi: 10.1038/s41574-018-0118-x. Review.

PMID:
30446744
16.

Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes.

Clemmensen C, Jall S, Kleinert M, Quarta C, Gruber T, Reber J, Sachs S, Fischer K, Feuchtinger A, Karlas A, Simonds SE, Grandl G, Loher D, Sanchez-Quant E, Keipert S, Jastroch M, Hofmann SM, Nascimento EBM, Schrauwen P, Ntziachristos V, Cowley MA, Finan B, Müller TD, Tschöp MH.

Nat Commun. 2018 Oct 23;9(1):4304. doi: 10.1038/s41467-018-06769-y. Erratum in: Nat Commun. 2018 Nov 20;9(1):4975.

17.

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists.

Müller TD, Clemmensen C, Finan B, DiMarchi RD, Tschöp MH.

Pharmacol Rev. 2018 Oct;70(4):712-746. doi: 10.1124/pr.117.014803. Review.

PMID:
30087160
18.

An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation.

Khajavi N, Finan B, Kluth O, Müller TD, Mergler S, Schulz A, Kleinau G, Scheerer P, Schürmann A, Gudermann T, Tschöp MH, Krude H, DiMarchi RD, Biebermann H.

Cell Signal. 2018 Nov;51:13-22. doi: 10.1016/j.cellsig.2018.07.006. Epub 2018 Jul 25.

PMID:
30055232
19.

Metabolic syndrome and extensive adipose tissue inflammation in morbidly obese Göttingen minipigs.

Renner S, Blutke A, Dobenecker B, Dhom G, Müller TD, Finan B, Clemmensen C, Bernau M, Novak I, Rathkolb B, Senf S, Zöls S, Roth M, Götz A, Hofmann SM, Hrabĕ de Angelis M, Wanke R, Kienzle E, Scholz AM, DiMarchi R, Ritzmann M, Tschöp MH, Wolf E.

Mol Metab. 2018 Oct;16:180-190. doi: 10.1016/j.molmet.2018.06.015. Epub 2018 Jun 28.

20.

Clearance kinetics of the VGF-derived neuropeptide TLQP-21.

Guo Z, Sahu BS, He R, Finan B, Cero C, Verardi R, Razzoli M, Veglia G, Di Marchi RD, Miles JM, Bartolomucci A.

Neuropeptides. 2018 Oct;71:97-103. doi: 10.1016/j.npep.2018.06.003. Epub 2018 Jun 19.

21.

Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21.

Kim T, Nason S, Holleman C, Pepin M, Wilson L, Berryhill TF, Wende AR, Steele C, Young ME, Barnes S, Drucker DJ, Finan B, DiMarchi R, Perez-Tilve D, Tschöp M, Habegger KM.

Diabetes. 2018 Sep;67(9):1773-1782. doi: 10.2337/db17-1502. Epub 2018 Jun 20.

22.

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.

Capozzi ME, DiMarchi RD, Tschöp MH, Finan B, Campbell JE.

Endocr Rev. 2018 Oct 1;39(5):719-738. doi: 10.1210/er.2018-00117. Review.

PMID:
29905825
23.

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.

Agrawal A, Parlee S, Perez-Tilve D, Li P, Pan J, Mroz PA, Kruse Hansen AM, Andersen B, Finan B, Kharitonenkov A, DiMarchi RD.

Mol Metab. 2018 Jul;13:45-55. doi: 10.1016/j.molmet.2018.05.003. Epub 2018 May 11.

24.

Optimization of peptide-based polyagonists for treatment of diabetes and obesity.

Knerr PJ, Finan B, Gelfanov V, Perez-Tilve D, Tschöp MH, DiMarchi RD.

Bioorg Med Chem. 2018 Jun 1;26(10):2873-2881. doi: 10.1016/j.bmc.2017.10.047. Epub 2017 Nov 2. Review. No abstract available.

PMID:
29153547
25.

Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity.

Quarta C, Clemmensen C, Zhu Z, Yang B, Joseph SS, Lutter D, Yi CX, Graf E, García-Cáceres C, Legutko B, Fischer K, Brommage R, Zizzari P, Franklin BS, Krueger M, Koch M, Vettorazzi S, Li P, Hofmann SM, Bakhti M, Bastidas-Ponce A, Lickert H, Strom TM, Gailus-Durner V, Bechmann I, Perez-Tilve D, Tuckermann J, Hrabě de Angelis M, Sandoval D, Cota D, Latz E, Seeley RJ, Müller TD, DiMarchi RD, Finan B, Tschöp MH.

Cell Metab. 2017 Oct 3;26(4):620-632.e6. doi: 10.1016/j.cmet.2017.08.023. Epub 2017 Sep 21.

26.

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.

Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi RD, Tschöp MH, Müller TD, Hofmann SM.

Mol Metab. 2017 Mar 1;6(5):440-446. doi: 10.1016/j.molmet.2017.02.002. eCollection 2017 May.

27.

Alternatively activated macrophages do not synthesize catecholamines or contribute to adipose tissue adaptive thermogenesis.

Fischer K, Ruiz HH, Jhun K, Finan B, Oberlin DJ, van der Heide V, Kalinovich AV, Petrovic N, Wolf Y, Clemmensen C, Shin AC, Divanovic S, Brombacher F, Glasmacher E, Keipert S, Jastroch M, Nagler J, Schramm KW, Medrikova D, Collden G, Woods SC, Herzig S, Homann D, Jung S, Nedergaard J, Cannon B, Tschöp MH, Müller TD, Buettner C.

Nat Med. 2017 May;23(5):623-630. doi: 10.1038/nm.4316. Epub 2017 Apr 17.

28.

The New Biology and Pharmacology of Glucagon.

Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH.

Physiol Rev. 2017 Apr;97(2):721-766. doi: 10.1152/physrev.00025.2016. Review.

29.

Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.

Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Müller L, De Angelis M, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Liu P, Tuckermann J, Malehmir M, Healy ME, Weber A, Heikenwalder M, Jastroch M, Kleinert M, Jall S, Brandt S, Flamant F, Schramm KW, Biebermann H, Döring Y, Weber C, Habegger KM, Keuper M, Gelfanov V, Liu F, Köhrle J, Rozman J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Hofmann SM, Yang B, Tschöp MH, DiMarchi R, Müller TD.

Cell. 2016 Oct 20;167(3):843-857.e14. doi: 10.1016/j.cell.2016.09.014. Epub 2016 Oct 6.

30.

Fibroblast activation protein (FAP) as a novel metabolic target.

Sánchez-Garrido MA, Habegger KM, Clemmensen C, Holleman C, Müller TD, Perez-Tilve D, Li P, Agrawal AS, Finan B, Drucker DJ, Tschöp MH, DiMarchi RD, Kharitonenkov A.

Mol Metab. 2016 Jul 16;5(10):1015-1024. doi: 10.1016/j.molmet.2016.07.003. eCollection 2016 Oct.

31.

Determination of thyroid hormones in mouse tissues by isotope-dilution microflow liquid chromatography-mass spectrometry method.

De Angelis M, Giesert F, Finan B, Clemmensen C, Müller TD, Vogt-Weisenhorn D, Tschöp MH, Schramm KW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:413-420. doi: 10.1016/j.jchromb.2016.08.037. Epub 2016 Aug 26.

PMID:
27649501
32.

GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight.

Vogel H, Wolf S, Rabasa C, Rodriguez-Pacheco F, Babaei CS, Stöber F, Goldschmidt J, DiMarchi RD, Finan B, Tschöp MH, Dickson SL, Schürmann A, Skibicka KP.

Neuropharmacology. 2016 Nov;110(Pt A):396-406. doi: 10.1016/j.neuropharm.2016.07.039. Epub 2016 Aug 2.

33.

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.

Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD, DiMarchi RD.

Cell Metab. 2016 Jul 12;24(1):51-62. doi: 10.1016/j.cmet.2016.06.021. Review.

34.

Reappraisal of GIP Pharmacology for Metabolic Diseases.

Finan B, Müller TD, Clemmensen C, Perez-Tilve D, DiMarchi RD, Tschöp MH.

Trends Mol Med. 2016 May;22(5):359-376. doi: 10.1016/j.molmed.2016.03.005. Epub 2016 Mar 30. Review.

PMID:
27038883
35.

Hypothalamic leptin action is mediated by histone deacetylase 5.

Kabra DG, Pfuhlmann K, García-Cáceres C, Schriever SC, Casquero García V, Kebede AF, Fuente-Martin E, Trivedi C, Heppner K, Uhlenhaut NH, Legutko B, Kabra UD, Gao Y, Yi CX, Quarta C, Clemmensen C, Finan B, Müller TD, Meyer CW, Paez-Pereda M, Stemmer K, Woods SC, Perez-Tilve D, Schneider R, Olson EN, Tschöp MH, Pfluger PT.

Nat Commun. 2016 Feb 29;7:10782. doi: 10.1038/ncomms10782.

36.

Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists.

Finan B, Clemmensen C, Müller TD.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:42-54. doi: 10.1016/j.mce.2015.07.003. Epub 2015 Jul 4. Review.

PMID:
26151488
37.

Current and Emerging Treatment Options in Diabetes Care.

Clemmensen C, Müller TD, Finan B, Tschöp MH, DiMarchi R.

Handb Exp Pharmacol. 2016;233:437-59. doi: 10.1007/164_2015_7. Review.

PMID:
25903416
38.

Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.

Clemmensen C, Finan B, Fischer K, Tom RZ, Legutko B, Sehrer L, Heine D, Grassl N, Meyer CW, Henderson B, Hofmann SM, Tschöp MH, Van der Ploeg LH, Müller TD.

EMBO Mol Med. 2015 Mar;7(3):288-98. doi: 10.15252/emmm.201404508.

39.

GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice.

Schwenk RW, Baumeier C, Finan B, Kluth O, Brauer C, Joost HG, DiMarchi RD, Tschöp MH, Schürmann A.

Diabetologia. 2015 Mar;58(3):604-14. doi: 10.1007/s00125-014-3478-3. Epub 2014 Dec 20.

40.

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, Riboulet W, Funk J, Hertel C, Belli S, Sebokova E, Conde-Knape K, Konkar A, Drucker DJ, Gelfanov V, Pfluger PT, Müller TD, Perez-Tilve D, DiMarchi RD, Tschöp MH.

Nat Med. 2015 Jan;21(1):27-36. doi: 10.1038/nm.3761. Epub 2014 Dec 8.

PMID:
25485909
41.

Hypothalamic PGC-1α protects against high-fat diet exposure by regulating ERα.

Morselli E, Fuente-Martin E, Finan B, Kim M, Frank A, Garcia-Caceres C, Navas CR, Gordillo R, Neinast M, Kalainayakan SP, Li DL, Gao Y, Yi CX, Hahner L, Palmer BF, Tschöp MH, Clegg DJ.

Cell Rep. 2014 Oct 23;9(2):633-45. doi: 10.1016/j.celrep.2014.09.025. Epub 2014 Oct 16.

42.

Dietary triglycerides act on mesolimbic structures to regulate the rewarding and motivational aspects of feeding.

Cansell C, Castel J, Denis RG, Rouch C, Delbes AS, Martinez S, Mestivier D, Finan B, Maldonado-Aviles JG, Rijnsburger M, Tschöp MH, DiLeone RJ, Eckel RH, la Fleur SE, Magnan C, Hnasko TS, Luquet S.

Mol Psychiatry. 2014 Oct;19(10):1095-105. doi: 10.1038/mp.2014.31. Epub 2014 Apr 15.

43.

GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet.

Clemmensen C, Chabenne J, Finan B, Sullivan L, Fischer K, Küchler D, Sehrer L, Ograjsek T, Hofmann SM, Schriever SC, Pfluger PT, Pinkstaff J, Tschöp MH, Dimarchi R, Müller TD.

Diabetes. 2014 Apr;63(4):1422-7. doi: 10.2337/db13-1609. Epub 2013 Dec 30.

44.

The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor.

Fischer K, Finan B, Clemmensen C, van der Ploeg LH, Tschöp MH, Müller TD.

Front Nutr. 2015 Jan 12;1:31. doi: 10.3389/fnut.2014.00031. eCollection 2014.

45.

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschöp MH.

Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.

46.

Estrogen, astrocytes and the neuroendocrine control of metabolism.

Fuente-Martin E, Garcia-Caceres C, Morselli E, Clegg DJ, Chowen JA, Finan B, Brinton RD, Tschöp MH.

Rev Endocr Metab Disord. 2013 Dec;14(4):331-8. doi: 10.1007/s11154-013-9263-7. Review.

47.

The orphan receptor Gpr83 regulates systemic energy metabolism via ghrelin-dependent and ghrelin-independent mechanisms.

Müller TD, Müller A, Yi CX, Habegger KM, Meyer CW, Gaylinn BD, Finan B, Heppner K, Trivedi C, Bielohuby M, Abplanalp W, Meyer F, Piechowski CL, Pratzka J, Stemmer K, Holland J, Hembree J, Bhardwaj N, Raver C, Ottaway N, Krishna R, Sah R, Sallee FR, Woods SC, Perez-Tilve D, Bidlingmaier M, Thorner MO, Krude H, Smiley D, DiMarchi R, Hofmann S, Pfluger PT, Kleinau G, Biebermann H, Tschöp MH.

Nat Commun. 2013;4:1968. doi: 10.1038/ncomms2968.

48.

G-protein coupled receptor 83 (GPR83) signaling determined by constitutive and zinc(II)-induced activity.

Müller A, Kleinau G, Piechowski CL, Müller TD, Finan B, Pratzka J, Grüters A, Krude H, Tschöp M, Biebermann H.

PLoS One. 2013;8(1):e53347. doi: 10.1371/journal.pone.0053347. Epub 2013 Jan 15.

49.

p62 links β-adrenergic input to mitochondrial function and thermogenesis.

Müller TD, Lee SJ, Jastroch M, Kabra D, Stemmer K, Aichler M, Abplanalp B, Ananthakrishnan G, Bhardwaj N, Collins S, Divanovic S, Endele M, Finan B, Gao Y, Habegger KM, Hembree J, Heppner KM, Hofmann S, Holland J, Küchler D, Kutschke M, Krishna R, Lehti M, Oelkrug R, Ottaway N, Perez-Tilve D, Raver C, Walch AK, Schriever SC, Speakman J, Tseng YH, Diaz-Meco M, Pfluger PT, Moscat J, Tschöp MH.

J Clin Invest. 2013 Jan;123(1):469-78. doi: 10.1172/JCI64209. Epub 2012 Dec 21.

50.

Targeted estrogen delivery reverses the metabolic syndrome.

Finan B, Yang B, Ottaway N, Stemmer K, Müller TD, Yi CX, Habegger K, Schriever SC, García-Cáceres C, Kabra DG, Hembree J, Holland J, Raver C, Seeley RJ, Hans W, Irmler M, Beckers J, de Angelis MH, Tiano JP, Mauvais-Jarvis F, Perez-Tilve D, Pfluger P, Zhang L, Gelfanov V, DiMarchi RD, Tschöp MH.

Nat Med. 2012 Dec;18(12):1847-56. doi: 10.1038/nm.3009. Epub 2012 Nov 11.

Supplemental Content

Support Center